Detection of FGFR Gene Mutations in the Tumor Tissue and Urine of Patients With Urothelial Carcinoma

Ho Kyung Seo92 enrolled

Overview

This study aims to compare the correlation between FGFR mutations found in bladder cancer tissues and urine to develop a companion diagnostic method for predicting the effect of FGFR inhibitors using urine samples of the patients with urothelial cancer.

This study targets 92 patients with urothelial cancer, whose tissue (from scheduled surgery) and urine samples can be obtained, regardless of the treatment stage. ■ Examination Methods * FGFR mutations in bladder cancer tissues will be analyzed using next-generation sequencing and current companion diagnostic methods. * FGFR mutations in urine samples obtained from patients with bladder cancer will be analyzed using nanowires. * Bladder cancer subtyping will be performed by RNA sequencing of tumor tissues or other methods. * Analysis of paired tissues before and after chemotherapy will be performed on transurethral resection of bladder tumor (TUR-BT) and cystectomy tissues before and after neoadjuvant chemotherapy.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Bladder Cancer

Interventions

FGFR testDIAGNOSTIC_TEST

Detection of FGFR gene mutations in the tumor tissue and urine of patients

Eligibility

Sex: ALLMin age: 20 YearsMax age: 90 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Suspected patients of urothelial cancer who will visit the National Cancer Center Korea from the date of Institutional Review Board (IRB) approval to 2021 and with identified tumors in the bladder according to bladder endoscopy. * Subjects who are scheduled for surgery (transurethral bladder tumor resection, radical bladder resection, and radical bladder ureterectomy) and have agreed to participate in the study Exclusion Criteria: * History of other active malignant tumors treated within 24 months * Patients with either mental illness or who cannot participate in clinical trials at the judgment of other doctors * If patients and guardians do not want to participate in this study * History of having administered FGFR inhibitors in the past

Outcomes

Primary Outcomes

Correlation between FGFR mutations found in bladder cancer tissues and urine before and after treatment

The ratio of patients with matching test results to total patients

Time frame: Up to two weeks before and after surgery

Secondary Outcomes

Changes in FGFR mutations in tissues before and after treatment

Changes in FGFR mutations in tissues before and after treatment will be observed in the patients with muscle-invasive and non-muscle-invasive bladder cancer undergoing neoadjuvant chemotherapy and transurethral bladder tumor resection, respectively, due to recurrence.

Time frame: Up to two weeks before and after treatment

Patient prognosis

recurrence-free

Time frame: six months and one year after treatment

Patient prognosis

progression-free

Time frame: six months and one year after treatment

Patient prognosis

cancer-specific survivals

Time frame: six months and one year after treatment

Patient prognosis

overall survivals

Time frame: six months and one year after treatment

PD-L1 expression

PD-L1 expression level will be measured using immunohistochemistry, RNA sequencing, and other suitable methods to analyze the bladder cancer subtypes

Time frame: Up to two weeks before and after treatment

Central Contacts

Ho Kyung Seo, MD, PhD

CONTACT

+82-31-920-1678 seohk@ncc.re.kr

Sahyun Pak, MD

CONTACT

+82-31-920-2794 sahyun@ncc.re.kr

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.